Markets Spin Toward Cyclicals

Markets Spin Toward Cyclicals

A slump in tech stocks may explain the market rotation – but it’s the earnings season that investors need to watch, says CIO and Chief US Equity Strategist Mike Wilson.


----- Transcript -----


Welcome to Thoughts on the Market. I'm Mike Wilson, Morgan Stanley’s CIO and Chief US Equity Strategist. Along with my colleagues bringing you a variety of perspectives, today I'll be talking about the recent rotation toward more cyclical parts of the equity market.

It's Monday, Oct 14th at 11:30am in New York.

So let’s get after it.

Last Monday, we upgraded cyclicals relative to defensives after taking profits in our defensive overweight two weeks prior. These calls come on the back of September's strong jobs report and our economists' expectation for the Fed to still cut interest rates into next year. The resilient labor report effectively reverses the softness we saw in labor markets over the summer which had re-introduced hard landing risks into the markets, driving big outperformance in bonds and defensive stocks. In short, it was a good time to lock in profits after an historically good run.

Indeed, cyclical stocks have delivered better performance with these improved macro data. Importantly, the rates market is confirming this move. Oftentimes, the rates market tends to hold onto growth risks longer than the equity market. Thus, the recent move higher in yields following resilient data suggests the bond market pricing is shedding some of its growth concerns, and giving us more confidence in our cyclicals upgrade.

Furthermore, our cyclical overweights at the sector level in Industrials, Financials and Energy are all exhibiting a positive correlation to rates. Conversely, defensives are exhibiting a negative correlation to yields. In other words, good macro data is still good for many large cap cyclical stocks, while it's bad for defensives. Thus, further stabilization in the economic surprise index should continue to support quality cyclicals' relative performance even if it comes amid higher yields.

Meanwhile, positioning in cyclicals remains light amongst our institutional client base. This is particularly true for Financials. In our view, this creates opportunity in a sector that we upgraded to overweight last week. This upgrade was based on rebounding capital markets activity, a better loan growth environment in 2025, an acceleration in buybacks post Basel Endgame re-proposal, and attractive relative valuation. Finally, we also factored in the notion that several large cap bank stocks had de-risked in mid-September with lowered guidance ahead of earnings season. Initial results from earnings season last week indicate that large cap banks are clearing that lowered hurdle. On the other side of the coin, positioning in defensives and quality growth remains extended. This is consistent with our conversations with clients who generally remain positioned for a soft macro growth regime.

Given the significant influence of the Magnificent 7 stocks on the overall direction of the S&P 500, investors remain focused on how this group of stocks will trade into year-end. It's notable this cohort has underperformed since the second quarter earnings season, and relative performance just took another leg lower. The breadth among this group has been somewhat narrow with only one of the seven making new highs since the summer in both absolute and relative terms. In our view, this may be one of the reasons for the better performance in other areas of the market and is a potential driver of further broadening into cyclicals. Of course, if the market reverts back to these stocks, it’s a risk to our cyclical upgrade.

Earnings season will be an important factor in terms of these rotations. The fundamental reason for the underperformance of the Magnificent 7 could simply be the deceleration in earnings growth from the very strong pace last year. If this underperformance continues, it could provide further fuel for the quality cyclicals to continue to do better as we expect. Conversely, if earnings revisions show relative strength for the Mag 7, these stocks will likely outperform once again and market leadership may narrow—like it did during [the] second quarter and all of 2023.

Thanks for listening. If you enjoy the podcast, leave us a review wherever you listen, and share Thoughts on the Market with a friend or colleague today.

Jaksot(1515)

Andrew Sheets: Inflation - When to Turn Down the Music?

Andrew Sheets: Inflation - When to Turn Down the Music?

The expectation of increased inflation is stirring concerns among investors, but the actual market for expected inflation suggests the Fed is on the right track.

26 Maalis 20213min

Special Episode: Diverging Emerging Markets

Special Episode: Diverging Emerging Markets

Amid a generally conservative outlook for emerging markets, key differentiators are their scope for policy action, pace of vaccine rollout and equity valuations.

25 Maalis 20219min

Michael Zezas: U.S./China Trade - No Quick Path to Lower Barriers

Michael Zezas: U.S./China Trade - No Quick Path to Lower Barriers

Most Trump era barriers remain in place and new ones may even be implemented by the current administration. Markets should pay attention.

24 Maalis 20212min

Brian Nowak: New Online Habits vs. A Return to ‘Normal’

Brian Nowak: New Online Habits vs. A Return to ‘Normal’

The Internet sector is more essential than ever. Our analyst looks at where pandemic habits will be stickiest and where the return to ‘normal’ may limit it.

23 Maalis 20214min

Mike Wilson: Outside the Consensus

Mike Wilson: Outside the Consensus

We forecast a shorter and hotter business cycle than the consensus estimates, suggesting a move to mid-cycle portfolio positions earlier than expected.

22 Maalis 20213min

Special Episode: The Winding Road to Herd Immunity, Pt. 2

Special Episode: The Winding Road to Herd Immunity, Pt. 2

Chief Cross-Asset Strategist Andrew Sheets and Biotech equity analyst Matthew Harrison continue their conversation, with a focus on international progress for COVID-19 vaccinations.

19 Maalis 20218min

Special Episode: The Winding Road to Herd Immunity

Special Episode: The Winding Road to Herd Immunity

Chief Cross-Asset Strategist Andrew Sheets talks with Biotech equity analyst Matthew Harrison on dose availability, vaccine hesitancy and the timeline for herd immunity.

18 Maalis 20219min

Michael Zezas: Three Revealing Numbers from the Stimulus Package

Michael Zezas: Three Revealing Numbers from the Stimulus Package

It may be hard for investors to conceptualize how substantial the impact of the American Rescue Plan Act may be, but three numbers provide perspective.

17 Maalis 20212min

Suosittua kategoriassa Liike-elämä ja talous

sijotuskasti
psykopodiaa-podcast
mimmit-sijoittaa
rss-rahapodi
rss-rahamania
herrasmieshakkerit
ostan-asuntoja-podcast
pari-sanaa-lastensuojelusta
rss-lahtijat
oppimisen-psykologia
lakicast
taloudellinen-mielenrauha
rss-neuvottelija-sami-miettinen
yrittaja
rss-startup-ministerio
rss-myynti-ei-ole-kirosana
hyva-paha-johtaminen
rss-myyntikoulu
rss-karon-grilli
rss-seuraava-potilas